Clinical laboratory roles have so far ranked among the least vulnerable to AI displacement in recent workforce research, and health system executives have largely described automation as a reallocation of duties rather than a wave of job cuts.
Still, when more than 100 healthcare leaders named their most pressing 2026 workforce challenge, managing the relationship between AI and staff topped the list. The FDA’s authorization of Vitestro’s Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention, is an early test case — and hospital and lab leaders are already weighing what it could mean for their own workforce.
Pamela Sun, executive director of pathology and laboratory medicine at Cleveland Clinic, expects the technology to extend phlebotomists’ capacity rather than eliminate their role. In an outpatient setting, she said, the workflow could shift so a patient is seated and positioned at the device, which then automates site preparation, vein detection and the draw itself, while a trained phlebotomist oversees the process and potentially supervises more than one device depending on volume and lab footprint.
“From a staffing standpoint, devices like this could be a supplement rather than a replacement,” Ms. Sun said. “It does not remove the front-end parts of the workflow, like registration, check-in and patient ID verification.”
Diana Cardona, MD, chief clinical officer for Charlotte, N.C.-based Advocate Health clinical laboratories and chair of the department of pathology at Wake Forest University School of Medicine, sees a similar dynamic.
“No single technology is going to solve that challenge, but innovations like this could help health systems keep pace with demand while making testing more accessible and convenient for patients,” she said, adding that the real opportunity isn’t just automating a blood draw but “enabling skilled professionals to extend their expertise across multiple collection points while maintaining clinical oversight.”
Realizing that potential first requires solving real operational math, according to MS. Sun. Before Aletta could meaningfully ease the phlebotomist shortage, labs would need enough physical space to house the right number of devices for their volume, plus a clear sense of the ideal phlebotomist-to-device ratio — one that maintains throughput and patient experience while still accounting for maintenance, restocking and supervision between collections.
Advocate Health is already an early collaboration partner with Vitestro as the company develops its robotic phlebotomy platform, according to Dr. Cardona, who said the system’s interest is driven by access and convenience.
“If blood collection can be performed more conveniently in the community setting or even at home, it could support chronic disease monitoring, preventative care, clinical research and virtual care models that otherwise require patients to travel, sometimes long distances, for laboratory testing,” she said.
Both leaders see the FDA authorization as a catalyst for automation that goes further still. Ms. Sun described a “cradle to grave” vision, in which the blood draw connects directly to pre-analytical processing and testing platforms with little manual handling in between, and pointed to longer-term potential for direct-to-consumer collection sites where patients could get blood drawn without a traditional appointment. But she flagged a limit to where the technology fits today: Aletta is built for outpatient settings, while the phlebotomy shortage tends to bite hardest on the inpatient side, where workflows are more complex and patient acuity is higher.
Dr. Cardona framed the moment as an opportunity for Advocate Health to help shape where laboratory medicine goes next, though she cautioned that any such technology still has to prove out quality, safety, reliability and patient acceptance before wider adoption.
